Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.70 |
| ▸ | GPR34 | Q9UPC5 | 8/20 | 0.64 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973755 | 0.90 | KIFC1 (0.59) | KIFC1GPR34PPARGFFAR1CAPN1 | |
| SCHEMBL3971467 | 0.90 | KIFC1 (0.59) | KIFC1GPR34PPARGFFAR1CAPN1 | |
| SCHEMBL5927401 | 0.87 | KIFC1 (0.60) | KIFC1GPR34PPARGGPR132MME | |
| SCHEMBL1123243 | 0.85 | GPR132 (0.72) | GPR34PPARGGPR132MMEACE | |
| SCHEMBL1122833 | 0.85 | GPR132 (0.72) | GPR34PPARGGPR132MMEACE | |
| SCHEMBL5927205 | 0.85 | GPR132 (0.72) | GPR34PPARGGPR132MMEACE | |
| SCHEMBL4092410 | 0.84 | FFAR1 (0.53) | KIFC1GPR34FFAR1 | |
| SCHEMBL6029880 | 0.83 | GPR132 (0.73) | GPR34PPARGGPR132PTPN1 | |
| SCHEMBL6029879 | 0.82 | GPR34 (0.77) | GPR34PPARGGPR132MMEACE | |
| SCHEMBL5926994 | 0.82 | KIFC1 (0.62) | KIFC1GPR34GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677731-A4 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1677731-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | Aton Pharma, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005034880-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | KIFC1 4686/4885GPR34 955/4885PPARG 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.